Robert J Kreitman

List of Publications by Year
in descending order

201	11,635	25034	30922
papers	citations	57 h-index	102 g-index

203	203	203	6857
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600â€“Mutant Anaplastic Thyroid Cancer. Journal of Clinical Oncology, 2018, 36, 7-13.	1.6	630
2	Efficacy of the Anti-CD22 Recombinant Immunotoxin BL22 in Chemotherapy-Resistant Hairy-Cell Leukemia. New England Journal of Medicine, 2001, 345, 241-247.	27.0	509
3	Immunotoxin therapy of cancer. Nature Reviews Cancer, 2006, 6, 559-565.	28.4	475
4	Phase I Trial of Recombinant Immunotoxin Anti-Tac(Fv)-PE38 (LMB-2) in Patients With Hematologic Malignancies. Journal of Clinical Oncology, 2000, 18, 1622-1636.	1.6	416
5	Phase I Study of SS1P, a Recombinant Anti-Mesothelin Immunotoxin Given as a Bolus I.V. Infusion to Patients with Mesothelin-Expressing Mesothelioma, Ovarian, and Pancreatic Cancers. Clinical Cancer Research, 2007, 13, 5144-5149.	7.0	351
6	Immunotoxin Treatment of Cancer*. Annual Review of Medicine, 2007, 58, 221-237.	12.2	340
7	Phase I Trial of Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015 or HA22) in Patients With Hairy Cell Leukemia. Journal of Clinical Oncology, 2012, 30, 1822-1828.	1.6	287
8	Phase I Trial of Recombinant Immunotoxin RFB4(dsFv)-PE38 (BL22) in Patients With B-Cell Malignancies. Journal of Clinical Oncology, 2005, 23, 6719-6729.	1.6	262
9	Immunotoxins for targeted cancer therapy. AAPS Journal, 2006, 8, E532-E551.	4.4	258
10	High prevalence of MAP2K1 mutations in variant and IGHV4-34â€“expressing hairy-cell leukemias. Nature Genetics, 2014, 46, 8-10.	21.4	236
11	Phase I Trial of Continuous Infusion Anti-Mesothelin Recombinant Immunotoxin SS1P. Clinical Cancer Research, 2009, 15, 5274-5279.	7.0	209
12	Phase II Trial of Recombinant Immunotoxin RFB4(dsFv)-PE38 (BL22) in Patients With Hairy Cell Leukemia. Journal of Clinical Oncology, 2009, 27, 2983-2990.	1.6	208
13	Both variant and IGHV4-34â€“expressing hairy cell leukemia lack the BRAF V600E mutation. Blood, 2012, 119, 3330-3332.	1.4	202
14	Antibody Fusion Proteins: Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox. Clinical Cancer Research, 2011, 17, 6398-6405.	7.0	201
15	Immunotoxins in cancer therapy. Current Opinion in Immunology, 1999, 11, 570-578.	5.5	200
16	Major Cancer Regressions in Mesothelioma After Treatment with an Anti-Mesothelin Immunotoxin and Immune Suppression. Science Translational Medicine, 2013, 5, 208ra147.	12.4	198
17	Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. Blood, 2017, 129, 553-560.	1.4	193
18	Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia. Leukemia, 2018, 32, 1768-1777.	7.2	184

#	Article	IF	Citations
19	A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity. Blood, 2009, 113, 3792-3800.	1.4	174
20	Responses in Refractory Hairy Cell Leukemia to a Recombinant Immunotoxin. Blood, 1999, 94, 3340-3348.	1.4	161
21	Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 11782-11787.	7.1	145
22	Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for frontâ€line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125. Cancer, 2014, 120, 3311-3319.	4.1	144
23	VH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapy. Blood, 2009, 114, 4687-4695.	1.4	143
24	Anti-CD22 Immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-Positive Hematologic Malignancies of Childhood: Preclinical Studies and Phase I Clinical Trial. Clinical Cancer Research, 2010, 16, 1894-1903.	7.0	139
25	Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display. Clinical Cancer Research, 2002, 8, 995-1002.	7.0	135
26	Stabilization of the Fv fragments in recombinant immunotoxins by disulfide bonds engineered into conserved framework regions. Biochemistry, 1994, 33, 5451-5459.	2.5	134
27	Characterization of CD22 expression in acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2015, 62, 964-969.	1.5	129
28	Treatment of Hematologic Malignancies with Immunotoxins and Antibody-Drug Conjugates. Cancer Research, 2011, 71, 6300-6309.	0.9	119
29	Human neurological cancer cells express interleukin-4 (IL-4) receptors which are targets for the toxic effects of IL4-pseudomonas exotoxin chimeric protein. International Journal of Cancer, 1994, 58, 574-581.	5.1	112
30	CAT-8015: A Second-GenerationPseudomonasExotoxin Aâ€“Based Immunotherapy Targeting CD22-Expressing Hematologic Malignancies. Clinical Cancer Research, 2009, 15, 832-839.	7.0	107
31	Characterization of the B Cell Epitopes Associated with a Truncated Form of Pseudomonas Exotoxin (PE38) Used to Make Immunotoxins for the Treatment of Cancer Patients. Journal of Immunology, 2006, 177, 8822-8834.	0.8	104
32	Recombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T-cell epitopes. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 8571-8576.	7.1	104
33	Immunotoxins for leukemia. Blood, 2014, 123, 2470-2477.	1.4	102
34	Distinguishing hairy cell leukemia variant from hairy cell leukemia: Development and validation of diagnostic criteria. Leukemia Research, 2013, 37, 401-409.	0.8	100
35	Phase I trial of a novel diphtheria toxin/granulocyte macrophage colony-stimulating factor fusion protein (DT388GMCSF) for refractory or relapsed acute myeloid leukemia. Clinical Cancer Research, 2002, 8, 1004-13.	7.0	100
36	Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopes. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 5742-5747.	7.1	97

#	Article	IF	Citations
37	In Vitro Antibody Evolution Targeting Germline Hot Spots to Increase Activity of an Anti-CD22 Immunotoxin. Journal of Biological Chemistry, 2005, 280, 607-617.	3.4	96
38	Recombinant Immunotoxins Containing Truncated Bacterial Toxins for the Treatment of Hematologic Malignancies. BioDrugs, 2009, 23, 1-13.	4.6	85
39	An Early Step in Pseudomonas Exotoxin Action Is Removal of the Terminal Lysine Residue, Which Allows Binding to the KDEL Receptor. Biochemistry, 1997, 36, 14577-14582.	2.5	84
40	Thrombotic Microangiopathy with Targeted Cancer Agents. Clinical Cancer Research, 2011, 17, 5858-5866.	7.0	83
41	Complete regression of human B-cell lymphoma xenografts in mice treated with recombinant anti-CD22 immunotoxin RFB4(dsFv)-PE38 at doses tolerated by cynomolgus monkeys. , 1999, 81, 148-155.		81
42	Recombinant immunotoxins for treating cancer. International Journal of Medical Microbiology, 2004, 293, 577-582.	3.6	81
43	HA22 (R490A) Is a Recombinant Immunotoxin with Increased Antitumor Activity without an Increase in Animal Toxicity. Clinical Cancer Research, 2005, 11, 1545-1550.	7.0	78
44	Immunotoxins in the Treatment of Hematologic Malignancies. Current Drug Targets, 2006, 7, 1301-1311.	2.1	75
45	Recombinant Toxins Containing Human Granulocyte-Macrophage Colony-Stimulating Factor and Either Pseudomonas Exotoxin or Diphtheria Toxin Kill Gastrointestinal Cancer and Leukemia Cells. Blood, 1997, 90, 252-259.	1.4	72
46	Apoptosis induced by immunotoxins used in the treatment of hematologic malignancies. International Journal of Cancer, 2000, 87, 86-94.	5.1	70
47	Bendamustine and Rituximab in Relapsed and Refractory Hairy Cell Leukemia. Clinical Cancer Research, 2013, 19, 6313-6321.	7.0	70
48	Single-chain immunotoxin fusions between anti-tac and Pseudomonas exotoxin: Relative importance of the two toxin disulfide bonds. Bioconjugate Chemistry, 1993, 4, 112-120.	3.6	69
49	Minimal Residual Disease Detection in Hairy Cell Leukemia. American Journal of Clinical Pathology, 2003, 119, 213-217.	0.7	66
50	Selective Elimination of Human Regulatory T Lymphocytes In Vitro With the Recombinant Immunotoxin LMB-2. Journal of Immunotherapy, 2006, 29, 208-214.	2.4	66
51	New Monoclonal Antibodies to Mesothelin Useful for Immunohistochemistry, Fluorescence-Activated Cell Sorting, Western Blotting, and ELISA. Clinical Cancer Research, 2005, 11, 5840-5846.	7.0	65
52	The bruton tyrosine kinase inhibitor ibrutinib (<scp>PCI</scp>â€32765) blocks hairy cell leukaemia survival, proliferation and <scp>B</scp> cell receptor signalling: a new therapeutic approach. British Journal of Haematology, 2014, 166, 177-188.	2.5	65
53	Induction of caspase-dependent programmed cell death in B-cell chronic lymphocytic leukemia by anti-CD22 immunotoxins. Blood, 2004, 103, 2718-2726.	1.4	64
54	Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase 1 results and long-term follow-up. Blood, 2018, 131, 2331-2334.	1.4	64

#	Article	IF	Citations
55	Cladribine with Immediate Rituximab for the Treatment of Patients with Variant Hairy Cell Leukemia. Clinical Cancer Research, 2013, 19, 6873-6881.	7.0	62
56	Anti-Tumor Activity of K1-LysPE38QQR, an Immunotoxin Targeting Mesothelin, a Cell-Surface Antigen Overexpressed in Ovarian Cancer and Malignant Mesothelioma. Journal of Immunotherapy, 2000, 23, 473-479.	2.4	60
57	Inhibition of TNF-Î± Produced by Kupffer Cells Protects Against the Nonspecific Liver Toxicity of Immunotoxin Anti-Tac(Fv)-PE38, LMB-2. Journal of Immunology, 2000, 165, 7150-7156.	0.8	59
58	Characteristic CD103 and CD123 Expression Pattern Defines Hairy Cell Leukemia. American Journal of Clinical Pathology, 2011, 136, 625-630.	0.7	58
59	Randomized Phase II Study of First-Line Cladribine With Concurrent or Delayed Rituximab in Patients With Hairy Cell Leukemia. Journal of Clinical Oncology, 2020, 38, 1527-1538.	1.6	58
60	Variables affecting the quantitation of CD22 in neoplastic B cells. Cytometry Part B - Clinical Cytometry, 2011, 80B, 83-90.	1.5	57
61	Phase 1 study of the anti-CD22 immunotoxin moxetumomab pasudotox for childhood acute lymphoblastic leukemia. Blood, 2017, 130, 1620-1627.	1.4	57
62	TargetingPseudomonasexotoxin to hematologic malignancies. Seminars in Cancer Biology, 1995, 6, 297-306.	9.6	52
63	Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial. Journal of Hematology and Oncology, 2021, 14, 35.	17.0	51
64	Complete Remissions of Adult T-cell Leukemia with Anti-CD25 Recombinant Immunotoxin LMB-2 and Chemotherapy to Block Immunogenicity. Clinical Cancer Research, 2016, 22, 310-318.	7.0	48
65	Immunotoxin therapy of hematologic malignancies. Seminars in Oncology, 2003, 30, 545-557.	2.2	46
66	Expression and purification of the recombinant diphtheria fusion toxin DT388IL3 for phase I clinical trials. Protein Expression and Purification, 2004, 33, 123-133.	1.3	46
67	Recombinant Immunotoxins for the Treatment of Chemoresistant Hematologic Malignancies. Current Pharmaceutical Design, 2009, 15, 2652-2664.	1.9	45
68	Cytotoxic and antitumor activity of a recombinant immunotoxin composed of disulfide-stabilized anti-TAC Fv fragment and truncatedpseudomonas exotoxin. International Journal of Cancer, 1994, 58, 142-149.	5.1	44
69	Interleukin-4 receptor-directed cytotoxin therapy of AIDS-associated Kaposi's sarcoma tumors in xenograft model. Nature Medicine, 1999, 5, 817-822.	30.7	44
70	Antibody Response to DTâ€“GM, a Novel Fusion Toxin Consisting of a Truncated Diphtheria Toxin (DT) Linked to Human Granulocyteâ€“Macrophage Colony Stimulating Factor (GM), during a Phase I Trial of Patients with Relapsed or Refractory Acute Myeloid Leukemia. Clinical Immunology, 2001, 100, 191-197.	3.2	44
71	Recombinant toxins for the treatment of cancer. Current Opinion in Molecular Therapeutics, 2003, 5, 44-51.	2.8	42
72	Recombinant Toxins That Bind to the Urokinase Receptor Are Cytotoxic without Requiring Binding to the Î±2-Macroglobulin Receptor. Journal of Biological Chemistry, 2000, 275, 7566-7573.	3.4	41

#	Article	IF	Citations
73	Sensitization of B-cell chronic lymphocytic leukemia cells to recombinant immunotoxin by immunostimulatory phosphorothioate oligodeoxynucleotides. Blood, 2002, 99, 1320-1326.	1.4	41
74	Releasable PEGylation of Mesothelin Targeted Immunotoxin SS1P Achieves Single Dosage Complete Regression of a Human Carcinoma in Mice. Bioconjugate Chemistry, 2007, 18, 773-784.	3.6	40
75	Phase 2 study of ibrutinib in classic and variant hairy cell leukemia. Blood, 2021, 137, 3473-3483.	1.4	40
76	Treatment with Combination of Dabrafenib and Trametinib in Patients with Recurrent/Refractory BRAF V600E-Mutated Hairy Cell Leukemia (HCL). Blood, 2018, 132, 391-391.	1.4	40
77	The cytotoxicity of anti-CD22 immunotoxin is enhanced by bryostatin 1 in B-cell lymphomas through CD22 upregulation and PKC-ÂII depletion. Haematologica, 2012, 97, 771-779.	3.5	37
78	Hairy cell leukemia: present and future directions. Leukemia and Lymphoma, 2019, 60, 2869-2879.	1.3	37
79	A Novel Anti-CD22 Immunotoxin, Moxetumomab Pasudotox: Phase I Study in Pediatric Acute Lymphoblastic Leukemia (ALL). Blood, 2011, 118, 248-248.	1.4	37
80	Interleukin-4 Receptor Expression on AIDS-Associated Kaposiâ€™s Sarcoma Cells and Their Targeting by a Chimeric Protein Comprised of Circularly Permuted Interleukin-4 and Pseudomonas Exotoxin. Molecular Medicine, 1997, 3, 327-338.	4.4	36
81	Somatic hypermutation and VH gene usage in hairy cell leukaemia. British Journal of Haematology, 2006, 133, 504-512.	2.5	35
82	Properties of chimeric toxins with two recognition domains: interleukin 6 and transforming growth factor .alpha. at different locations in Pseudomonas exotoxin. Bioconjugate Chemistry, 1992, 3, 63-68.	3.6	34
83	High-Level Expression and Purification of the Recombinant Diphtheria Fusion Toxin DTGM for PHASE I Clinical Trials. Protein Expression and Purification, 1999, 16, 190-201.	1.3	34
84	An improved recombinant Fab-immunotoxin targeting CD22 expressing malignancies. Leukemia Research, 2014, 38, 1224-1229.	0.8	34
85	111Indium-labeled monoclonal antibody K1: Biodistribution study in nude mice bearing a human carcinoma xenograft expressing mesothelin. , 1999, 80, 559-563.		33
86	Minimal Residual Disease in Hairy Cell Leukemia Patients Assessed by Clone-Specific Polymerase Chain Reaction. Clinical Cancer Research, 2006, 12, 2804-2811.	7.0	33
87	Novel anti-CD30 recombinant immunotoxins containing disulfide-stabilized Fv fragments. Clinical Cancer Research, 2002, 8, 2345-55.	7.0	32
88	Evidence of canonical somatic hypermutation in hairy cell leukemia. Blood, 2011, 117, 4844-4851.	1.4	31
89	Toxicology and Pharmacokinetics of DTGM, a Fusion Toxin Consisting of a Truncated Diphtheria Toxin (DT388) Linked to Human Granulocyte-Macrophage Colony-Stimulating Factor, in Cynomolgus Monkeys. Toxicology and Applied Pharmacology, 1999, 158, 152-160.	2.8	29
90	Minimal Residual Disease Detection in Hairy Cell Leukemia Comparison of Flow Cytometric Immunophenotyping With Clonal Analysis Using Consensus Primer Polymerase Chain Reaction for the Heavy Chain Gene. American Journal of Clinical Pathology, 2003, 119, 213-217.	0.7	29

#	Article	IF	Citations
91	Getting plant toxins to fuse. Leukemia Research, 1997, 21, 997-999.	0.8	28
92	Immunotoxins Targeting B cell Malignancyâ€"Progress and Problems With Immunogenicity. Biomedicines, 2019, 7, 1.	3.2	28
93	Hairy cell leukemia and COVID-19 adaptation of treatment guidelines. Leukemia, 2021, 35, 1864-1872.	7.2	28
94	Diphtheria toxin fused to granulocyte-macrophage colony-stimulating factor and Ara-C exert synergistic toxicity against human AML HL-60 cells. Leukemia Research, 1999, 23, 527-538.	0.8	27
95	Immunotoxins. Expert Opinion on Pharmacotherapy, 2000, 1, 1117-1129.	1.8	27
96	Soluble CD22 as a tumor marker for hairy cell leukemia. Blood, 2008, 112, 2272-2277.	1.4	27
97	Purification and characterization of IL6-PE4e, a recombinant fusion of interleukin 6 with Pseudomonas exotoxin. Bioconjugate Chemistry, 1993, 4, 581-585.	3.6	26
98	Cell-Specific Modulation of Drug Resistance in Acute Myeloid Leukemic Blasts by Diphtheria Fusion Toxin, DT388-GMCSF. Bioconjugate Chemistry, 1998, 9, 490-496.	3.6	26
99	Anti-Tac(Fab)-PE40, a recombinant double-chain immunotoxin which kills interleukin-2-receptor-bearing cells and induces complete remission in anin vivo tumor model. International Journal of Cancer, 1994, 57, 856-864.	5.1	25
100	Designing the Furin-Cleavable Linker in Recombinant Immunotoxins Based on Pseudomonas Exotoxin A. Bioconjugate Chemistry, 2015, 26, 1120-1128.	3.6	25
101	Efficacy and Safety of the Bruton Tyrosine Kinase Inhibitor Ibrutinib in Patients with Hairy Cell Leukemia: Stage 1 Results of a Phase 2 Study. Blood, 2016, 128, 1215-1215.	1.4	25
102	Molecular variant of hairy cell leukemia with poor prognosis. Leukemia and Lymphoma, 2011, 52, 99-102.	1.3	24
103	Immunoconjugates in the management of hairy cell leukemia. Best Practice and Research in Clinical Haematology, 2015, 28, 236-245.	1.7	24
104	Immunoconjugates and new molecular targets in hairy cell leukemia. Hematology American Society of Hematology Education Program, 2012, 2012, 660-666.	2.5	24
105	Immunotoxin BL22 induces apoptosis in mantle cell lymphoma (MCL) cells dependent on Bclâ€2 expression. British Journal of Haematology, 2010, 148, 99-109.	2.5	23
106	Recombinant immunotoxins and other therapies for relapsed/refractory hairy cell leukemia. Leukemia and Lymphoma, 2011, 52, 82-86.	1.3	23
107	Isolation of new anti-CD30 scFvs from DNA-immunized mice by phage display and biologic activity of recombinant immunotoxins produced by fusion with truncatedpseudomonas exotoxin. International Journal of Cancer, 2001, 92, 861-870.	5.1	22
108	Rational design of low immunogenic anti CD25 recombinant immunotoxin for T cell malignancies by elimination of T cell epitopes in PE38. Cellular Immunology, 2017, 313, 59-66.	3.0	21

#	Article	IF	Citations
109	Rational design of a chimeric toxin: an intramolecular location for the insertion of transforming growth factor .alpha. within Pseudomonas exotoxin as a targeting ligand. Bioconjugate Chemistry, 1992, 3, 58-62.	3.6	20
110	Immunobiological treatments of hairy-cell leukaemia. Best Practice and Research in Clinical Haematology, 2003, 16, 117-133.	1.7	20
111	Immunotoxins in the Treatment of Refractory Hairy Cell Leukemia. Hematology/Oncology Clinics of North America, 2006, 20, 1137-1151.	2.2	20
112	Immunotoxins with decreased immunogenicity and improved activity. Leukemia and Lymphoma, 2011, 52, 87-90.	1.3	20
113	Hairy Cell Leukemiaâ€"New Genes, New Targets. Current Hematologic Malignancy Reports, 2013, 8, 184-195.	2.3	20
114	Differential Expression of CD43, CD81, and CD200 in Classic Versus Variant Hairy Cell Leukemia. Cytometry Part B - Clinical Cytometry, 2019, 96, 275-282.	1.5	20
115	Development of Lymphoproliferative Disorder of Granular Lymphocytes in Association with Hairy Cell Leukemia. Leukemia and Lymphoma, 2000, 37, 97-104.	1.3	19
116	Synergistic Antitumor Activity of Anti-CD25 Recombinant Immunotoxin LMB-2 with Chemotherapy. Clinical Cancer Research, 2012, 18, 152-160.	7.0	19
117	Update on hairy cell leukemia. Clinical Advances in Hematology and Oncology, 2018, 16, 205-215.	0.3	19
118	Development of Recombinant Immunotoxins for Hairy Cell Leukemia. Biomolecules, 2020, 10, 1140.	4.0	18
119	Recombinant immunotoxins for the treatment of haematological malignancies. Expert Opinion on Biological Therapy, 2004, 4, 1115-1128.	3.1	17
120	Quantification of Expression of Antigens Targeted by Antibody-Based Therapy in Chronic Lymphocytic Leukemia. American Journal of Clinical Pathology, 2013, 140, 813-818.	0.7	17
121	Immunoconjugates and new molecular targets in hairy cell leukemia. Hematology American Society of Hematology Education Program, 2012, 2012, 660-6.	2.5	17
122	Site-Specific Conjugation to Interleukin 4 Containing Mutated Cysteine Residues Produces Interleukin 4-Toxin Conjugates with Improved Binding and Activity. Biochemistry, 1994, 33, 11637-11644.	2.5	16
123	Circularly permuted interleukin 4 retains proliferative and binding activity. Cytokine, 1995, 7, 311-318.	3.2	16
124	BL22 and lymphoid malignancies. Best Practice and Research in Clinical Haematology, 2006, 19, 685-699.	1.7	16
125	Characterization of T-cell repertoire in hairy cell leukemia patients before and after recombinant immunotoxin BL22 therapy. Cancer Immunology, Immunotherapy, 2006, 55, 1100-1110.	4.2	16
126	The improvement of an anti-CD22 immunotoxin. MAbs, 2011, 3, 479-486.	5.2	15

#	Article	IF	Citations
127	Contextualizing the Use of Moxetumomab Pasudotox in the Treatment of Relapsed or Refractory Hairy Cell Leukemia. Oncologist, 2020, 25, e170-e177.	3.7	15
128	Approach to the patient after relapse of hairy cell leukemia. Leukemia and Lymphoma, 2009, 50, 32-37.	1.3	14
129	Response of hairy cell leukemia to bendamustine. Leukemia and Lymphoma, 2011, 52, 1153-1156.	1.3	14
130	Taming ricin toxin. Nature Biotechnology, 2003, 21, 372-374.	17.5	13
131	Effect of Antigen Shedding on Targeted Delivery of Immunotoxins in Solid Tumors from a Mathematical Model. PLoS ONE, 2014, 9, e110716.	2.5	13
132	Class II human leucocyte antigen DRB1*11 in hairy cell leukaemia patients with and without haemolytic uraemic syndrome. British Journal of Haematology, 2014, 166, 729-738.	2.5	13
133	Vemurafenib and Rituximab in Patients with Hairy Cell Leukemia Previously Treated with Moxetumomab Pasudotox. Journal of Clinical Medicine, 2021, 10, 2800.	2.4	13
134	Long term follow-up of a phase II study of cladribine with concurrent rituximab with hairy cell leukemia variant. Blood Advances, 2021, 5, 4807-4816.	5.2	13
135	Autonomic neuropathy in transgenic mice caused by immunotoxin targeting of the peripheral nervous system. , 1998, 51, 162-173.		12
136	Augmentation of the Activity of an Immunotoxin, Anti-Tac(Fv)-PE40KDEL, in T Cell Lines Infected with Human T Cell Leukemia Virus Type-I. Leukemia and Lymphoma, 2002, 43, 885-888.	1.3	12
137	Cladribine Analogues via O6-(Benzotriazolyl) Derivatives of Guanine Nucleosides. Molecules, 2015, 20, 18437-18463.	3.8	12
138	Usefulness of Dual Immunohistochemistry Staining in Detection of Hairy Cell Leukemia in Bone Marrow. American Journal of Clinical Pathology, 2020, 153, 322-327.	0.7	12
139	Sensitization of B-cell chronic lymphocytic leukemia cells to recombinant immunotoxin by immunostimulatory phosphorothioate oligodeoxynucleotides. Blood, 2002, 99, 1320-6.	1.4	12
140	Similarities in the Biodistribution of Iodine-Labeled Anti-Tac Single-Chain Disulfide-Stabilized Fv Fragment and Anti-Tac Disulfide-Stabilized Fv Fragment. Nuclear Medicine and Biology, 1998, 25, 387-393.	0.6	11
141	Recombinant fusion toxins for cancer treatment. Expert Opinion on Biological Therapy, 2002, 2, 785-791.	3.1	9
142	Concurrent chronic lymphocytic leukemia/small lymphocytic lymphoma and hairy cell leukemia: clinical, pathologic and molecular features. Leukemia and Lymphoma, 2020, 61, 3177-3187.	1.3	9
143	Population pharmacokinetics, efficacy, and safety of moxetumomab pasudotox in patients with relapsed or refractory hairy cell leukaemia. British Journal of Clinical Pharmacology, 2020, 86, 1367-1376.	2.4	9
144	Interleukin-4 receptor cytotoxin as therapy for human malignant pleural mesothelioma xenografts. Annals of Thoracic Surgery, 2004, 78, 436-443.	1.3	8

#	Article	IF	Citations
145	Impact of telomere length on survival in classic and variant hairy cell leukemia. Leukemia Research, 2015, 39, 1360-1366.	0.8	8
146	Moxetumomab pasudotox as re-treatment for heavily-pretreated relapsed hairy cell leukemia. Leukemia and Lymphoma, 2021, 62, 2812-2814.	1.3	8
147	Moxetumomab Pasudotox-Tdfk in Heavily Pretreated Patients with Relapsed/Refractory Hairy Cell Leukemia (HCL): Long-Term Follow-up from the Pivotal Phase 3 Trial. Blood, 2019, 134, 2808-2808.	1.4	8
148	Adhesion of Hairy Cells Leukemia (HCL) Cells to Stromal Cells Can Be Inhibited by Blocking VLA-4 Integrins and CXCR4 Chemokine Receptors. Blood, 2011, 118, 1760-1760.	1.4	8
149	Making Fusion Toxins to Target Leukemia and Lymphoma. , 2000, 25, 215-226.		7
150	Immunoglobulin light chain repertoire in hairy cell leukemia. Leukemia Research, 2007, 31, 1231-1236.	0.8	7
151	Phase I Clinical Trial of the Anti-CD22 Immunotoxin CAT-8015 (HA22) for Pediatric Acute Lymphoblastic Leukemia (ALL).. Blood, 2009, 114, 839-839.	1.4	7
152	Phase I Dose-Escalation Study of CAT-8015 (HA22), A CD22-Specific Targeted Immunotoxin, in Relapsed or Refractory Hairy Cell Leukemia.. Blood, 2009, 114, 888-888.	1.4	7
153	Sensitivity of human acute myeloid leukaemia to diphtheria toxin-GM-CSF fusion protein. British Journal of Haematology, 1997, 98, 952-959.	2.5	6
154	Sandwich ELISAs for soluble immunoglobulin superfamily receptor translocation-associated 2 (IRTA2)/FcRH5 (CD307) proteins in human sera. Clinical Chemistry and Laboratory Medicine, 2006, 44, 594-602.	2.3	6
155	Immunotoxins: From Design to Clinical Application. Biomolecules, 2021, 11, 1696.	4.0	6
156	PRAME expression in hairy cell leukemia. Leukemia Research, 2008, 32, 1400-1406.	0.8	5
157	Renal Excretion of Recombinant Immunotoxins ContainingPseudomonasExotoxin. Bioconjugate Chemistry, 2011, 22, 736-740.	3.6	5
158	Expression of the muscle-associated gene MYF6 in hairy cell leukemia. PLoS ONE, 2020, 15, e0227586.	2.5	5
159	Pre-Clinical Evaluation of the Anti-CD22 Immunotoxin CAT-8015 in Combination with Chemotherapy Agents for Childhood B-Precursor Acute Lymphoblastic Leukemia (Pre-B ALL).. Blood, 2007, 110, 865-865.	1.4	5
160	Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Blocks Hairy Cell Leukemia (HCL) Survival, Proliferation, and BCR Signaling: A New Therapeutic Approach for HCL. Blood, 2012, 120, 1802-1802.	1.4	5
161	Randomized phase II study of cladribine with simultaneous or delayed rituximab in patients with untreated hairy cell leukemia.. Journal of Clinical Oncology, 2019, 37, 7003-7003.	1.6	5
162	Treatment of hairy cell leukemia. Expert Review of Hematology, 2020, 13, 1107-1117.	2.2	4

#	Article	IF	Citations
163	Diagnosis and treatment of hairy cell leukemia as the COVID-19 pandemic continues. Blood Reviews, 2022, 51, 100888.	5.7	4
164	Pharmacokinetic Analysis Of Response In Hairy Cell Leukemia Treated By Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox. Blood, 2013, 122, 2871-2871.	1.4	4
165	Confirmation and prevention of targeted toxicity by a recombinant fusion toxin. Molecular Cancer Therapeutics, 2004, 3, 1691-2.	4.1	4
166	In search of genetic factors predisposing to familial hairy cell leukemia (HCL): exome-sequencing of four multiplex HCL pedigrees. Leukemia, 2020, 34, 1934-1938.	7.2	3
167	Regression of Adult T-Cell Leukemia with Anti-CD25 Recombinant Immunotoxin LMB-2 Preceded by Chemotherapy. Blood, 2011, 118, 2575-2575.	1.4	3
168	High Response Rate of Moxetumomab Pasudotox in Relapsed/Refractory Hairy Cell Leukemia Includes Eradication of Minimal Residual Disease: Potential Importance for Outcome. Blood, 2015, 126, 4161-4161.	1.4	3
169	Moxetumomab Pasudotox: Clinical Experience in Relapsed/Refractory Hairy Cell Leukemia. , 2019, 23, E52-E59.		3
170	An scFv phage clone that binds to human Î²2-microglobulin. Immunotechnology: an International Journal of Immunological Engineering, 1999, 4, 231-236.	2.4	2
171	Generation of antibody-based therapeutics targeting the idiotype of B-cell malignancies. Antibody Therapeutics, 2019, 2, 12-21.	1.9	2
172	Efficacy and safety of moxetumomab pasudotox (moxe) in adult patients (pts) with relapsed/refractory hairy cell leukemia (HCL) in relation to drug exposure, baseline disease burden, and immunogenicity.. Journal of Clinical Oncology, 2018, 36, 7060-7060.	1.6	2
173	Pharmacokinetics (PK), pharmacodynamics (PD) and immunogenicity of moxetumomab pasudotox (Moxe), an immunotoxin targeting CD22, in adult patients (Pts) with relapsed or refractory hairy cell leukemia (HCL).. Journal of Clinical Oncology, 2018, 36, 7061-7061.	1.6	2
174	Current Clinical Practice: Treatment of Hairy Cell Leukemia at the Close of the 20th Century. Hematology, 1999, 4, 283-303.	1.5	1
175	Removing a hair of doubt about BRAF targeting. Blood, 2015, 125, 1199-1200.	1.4	1
176	Long Term Follow-up of a Phase II Study of Cladribine with Concurrent Rituximab in Patients with Hairy Cell Leukemia Variant. Blood, 2019, 134, 1536-1536.	1.4	1
177	BL22, a Recombinant Anti-CD22 Immunotoxin, Induces Cell Cycle Arrest and Apoptosis in B-Cell Lymphoma.. Blood, 2004, 104, 4613-4613.	1.4	1
178	Targeting CD22 in Childhood B-Precursor Acute Lymphoblastic Leukemia (Pre-B ALL): Pre-Clinical Studies and Phase I Trial of the Anti-CD22 Immunotoxin CAT-3888 (BL22).. Blood, 2007, 110, 855-855.	1.4	1
179	Long Term Results of BL22 (CAT-3888) in Multiply Relapsed Hairy Cell Leukemia.. Blood, 2009, 114, 3442-3442.	1.4	1
180	Resolution of Hairy Cell Leukemia Minimal Residual Disease by Both BRAF and Clone-Specific Real-Time Quantitative PCR (RQ-PCR) After Treatment with Moxetumomab Pasudotox.. Blood, 2012, 120, 2896-2896.	1.4	1

#	Article	IF	Citations
181	Moxetumomab pasudotox and minimal residual disease in hairy cell leukemia.. Journal of Clinical Oncology, 2015, 33, 7079-7079.	1.6	1
182	Moxetumomab pasudotox in heavily pretreated patients with relapsed/refractory hairy cell leukemia: Results of a pivotal international study.. Journal of Clinical Oncology, 2018, 36, 7004-7004.	1.6	1
183	Real-World Evidence on Therapeutic Strategies and Treatment-Sequencing in Patients with Chronic Lymphocytic Leukemia: An International Study of Eric, the European Research Initiative on CLL. Blood, 2021, 138, 2635-2635.	1.4	1
184	Recombinant toxins in haematologic malignancies and solid tumours. Expert Opinion on Investigational Drugs, 1998, 7, 1405-1427.	4.1	0
185	Chimeric toxins in cancer treatment. Expert Opinion on Emerging Drugs, 2000, 5, 61-71.	1.1	0
186	Hairy Cell Leukemia. American Journal of Cancer, 2002, 1, 189-203.	0.4	0
187	Editorial Board Focus â€“ February 2007. Expert Opinion on Biological Therapy, 2007, 7, 157-160.	3.1	0
188	Synergistic targeting of leukemia with leukotoxin and chemotherapy. Leukemia Research, 2011, 35, 1438-1439.	0.8	0
189	Recombinant Immunotoxins. Cancer Drug Discovery and Development, 2014, , 569-584.	0.4	0
190	BL22: A Milestone in Targeting CD22. Milestones in Drug Therapy, 2017, , 151-176.	0.1	0
191	Phase 1 trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox combined with rituximab for relapsed/refractory hairy cell leukemia.. Journal of Clinical Oncology, 2021, 39, 7036-7036.	1.6	0
192	Immunotoxins. , 2003, , 391-433.		0
193	Interim Results of Secondary Endpoints From a Randomized Trial of Cladribine with Early Vs Delayed Rituximab for Treatment of Early Hairy Cell Leukemia. Blood, 2011, 118, 2856-2856.	1.4	0
194	Bendamustine and Rituximab for the Treatment of Multiply Relapsed Hairy Cell Leukemia,. Blood, 2011, 118, 3909-3909.	1.4	0
195	Presence and Absence of the BRAF V600E Mutation in Hairy Cell Leukemia and Its Variants. Blood, 2011, 118, 931-931.	1.4	0
196	Durability of complete remission by moxetumomab pasudotox (HA22 or CAT-8015) assessed by clone-specific real-time quantitative PCR (RQ-PCR).. Journal of Clinical Oncology, 2012, 30, 2503-2503.	1.6	0
197	The HLA-DRB1*11 Antigen Is Preferentially Expressed in Hairy Cell Leukemia, Particularly in Patients Who Had Hemolytic Uremic Syndrome with Recombinant Immunotoxin BL22.. Blood, 2012, 120, 2488-2488.	1.4	0
198	The Role of Novel Dual Color Immunohistochemistry in Detection of Minimal Hairy Cell Leukemia in Bone Marrow: A Study of 148 Cases. Blood, 2018, 132, 4859-4859.	1.4	0

#	Article	IF	Citations
199	Pooled safety summary for patients treated with the CD22-directed cytotoxin moxetumomab pasudotox-tdfk.. Journal of Clinical Oncology, 2019, 37, 7014-7014.	1.6	0
200	Monoclonal Antibodies in Cancer--Second International Congress. 29 August-1 September 2002, Banff, Canada. IDrugs: the Investigational Drugs Journal, 2002, 5, 1057-61.	0.7	0
201	Targeted therapies - First International Congress. IDrugs: the Investigational Drugs Journal, 2002, 5, 949-54.	0.7	0